Navigation Links
Mast cells give clues in diagnosis, treatment of dengue
Date:4/30/2013

DURHAM, N.C. -- A protein produced by mast cells in the immune system may predict which people infected with dengue virus will develop life-threatening complications, according to researchers at Duke Medicine and Duke-National University of Singapore (Duke-NUS).

Their study also found that in experiments in mice, a class of drugs commonly used to treat asthma by targeting the mast cells could help treat vascular symptoms associated with dengue infections. The findings were published in the online journal eLife on April 30, 2013.

Dengue virus is spread by mosquitoes and infects as many as 390 million people worldwide each year, according to new estimates published in the journal Nature. It is a significant health issue in tropical areas of the world including parts of Latin America and Asia, but Florida residents have reported cases in recent years.

No treatments are available for dengue virus, and serious cases can result in widespread vascular leakage and hemorrhaging.

In 2011, Duke researchers reported that mast cells, which help the body respond to bacteria and other pathogens, play a role in attacking dengue virus and halting its spread. This finding presented new avenues for research, given the existing classes of drugs that target mast cells or the products of mast cells once they are activated.

In one experiment in the current study of dengue virus in mice, the researchers found that certain classes of drugs commonly used to treat asthma are effective in limiting vascular leakage associated with dengue.

"It may not seem intuitive how asthma and dengue infection would be related and would respond to the same types of drugs, but because both diseases are promoted by mast cells, the cellular targets of the class of drugs is quite effective," said lead author Ashley L. St. John, PhD, assistant professor of emerging infectious diseases at Duke-NUS.

The researchers continued to investigate the role of mast cells in attacking dengue virus in humans, and identified a biomarker a mast cell-derived product that appeared to predict the illness' most severe cases in human patients.

Most patients infected by a dengue virus develop a high fever, dubbed dengue fever, and recover on their own. However, a small number of these cases develop into dengue hemorrhagic fever, a dangerous condition marked by serious complications, including bleeding, respiratory distress and severe abdominal pain.

Until now, doctors have not been able to predict who will develop dengue hemorrhagic fever. When the researchers studied blood serum samples from patients with dengue infection, they found that the levels of a protein produced by mast cells, chymase, were significantly higher in the patients who developed dengue hemorrhagic fever compared to those who recovered after dengue fever.

"In addition to revealing a potential new way to diagnose and treat dengue infections, these findings may have much broader applicability for other infectious diseases where vascular leakage is a major pathologic outcome," said senior study author Soman N. Abraham, PhD, professor of pathology, immunology, and molecular genetics and microbiology at Duke Medicine and professor of emerging infectious diseases at Duke-NUS.


'/>"/>

Contact: Rachel Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Battery of tests on cancer cells shows them as squishy, yet tactically strong
2. New research findings on the brains guardian cells
3. Virus kills melanoma in animal model, spares normal cells
4. Screening detects ovarian cancer using neighboring cells
5. Method makes it easier to separate useful stem cells from problem ones for therapies
6. £2million project aims to revolutionize the study of cancer cells in the lab
7. Metastasis stem cells in the blood of breast cancer patients discovered
8. Voices Against Brain Cancer Comments on New Study Claiming Fat Tissue Stem Cells can Fight Brain Cancer
9. Ultrasound Waves, Bone Marrow Cells Show Promise in Heart Failure Patients
10. Stanford researchers turn skin cells directly into the cells that insulate neurons
11. Stem Cells to Relieve Low Back Pain?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... In the Health Care IT campaign, Robert Herjavec discusses health IT security ... will be attacked, but when.” However, he and many others involved highlight a promising ... in auditing and monitoring have taken security in health care a very long way. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney announced ... Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It ... Highway 121. , As the practice has grown, the need for more space has ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now ... . Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic ... Cut Pro X. , With ProGlass Prism users are given the tools and ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... this present generation. Yisrayl makes an astounding statement when he says that the ... that the Bible details the current times so plainly that anyone should be able ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Indiana Fiber Network ... the company later this year. Dyer started as the Chairman of the Management ... the establishment of the corporation including the recruitment of investor/owners and development of the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)...  The particle counters market is projected to ... 275.9 million in 2016, at a CAGR of ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical and ... growth in manufacturing industries in emerging nations are ... counters. On the other hand, technical limitations of ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
(Date:2/23/2017)... Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... innovative proprietary products for the urology market, will release ... ended December 31, 2016 before the market open on ... will host a conference call and webcast to discuss ... 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. ...
Breaking Medicine Technology: